Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Cancer Cell · 2025-04 · 43 (4) · 757-775.e8
DOI: 10.1016/j.ccell.2025.02.026 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2025-04. Verfasst von Housaiyin Li und 23 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Molecular Genetics a…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Head and Neck Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Molecular Genetics and Development Biology Graduate Program, University of Pittsburgh, Pit…
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- NIDCR NIH HHS
- University of Pittsburgh
- National Institutes of Health National Cancer Institute
- California Department of Fish and Game
- National Institutes of Health
- Bristol-Myers Squibb
Zitieren
APA
Li, H., Zandberg, D. P., Kulkarni, A., Chiosea, S. I., Santos, P. M., Isett, B. R., Joy, M., Sica, G. L., Contrera, K. J., Tatsuoka, C. M., Brand, M., Duvvuri, U., Kim, S., Kubik, M., Sridharan, S., Tu, F., Chen, J., Bruno, T. C., Vignali, D. A. A., …, & Ferris, R. L. (2025). Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell, 43(4), 757-775.e8. https://doi.org/10.1016/j.ccell.2025.02.026
Vancouver
Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, et al. Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025;43(4):757-775.e8. doi:10.1016/j.ccell.2025.02.026
BibTeX
@article{Li2025,
author = {Li, Housaiyin and Zandberg, Dan P and Kulkarni, Aditi and Chiosea, Simion I and Santos, Patricia M and Isett, Brian R and Joy, Marion and Sica, Gabriel L and Contrera, Kevin J and Tatsuoka, Curtis M and Brand, Matthias and Duvvuri, Umamaheswar and Kim, Seungwon and Kubik, Mark and Sridharan, Shaum and Tu, Fei and Chen, Jie and Bruno, Tullia C and Vignali, Dario A A and Cillo, Anthony R and Bao, Riyue and Wang, Jing Hong and Vujanovic, Lazar and Ferris, Robert L},
title = {Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {4},
pages = {757--775.e8},
doi = {10.1016/j.ccell.2025.02.026}
}
EUVIMED